Phase 2 Trial of Avastin (Bevacizumab) and FOLFIRI Produce ... Jan 30, 2006
...some clinical befit after being treated with a combination of the standard FOLFIRI regimen (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab (Avastin). ... - DG News
Pancreatic Cancer Patients Respond in Phase II Study of ... Jan 30, 2006
...metastatic pancreatic who were treated with an experimental protocol that included gemcitabine, cisplatin and the molecular targeting agent bevacizumab (Avastin ... - DG News
Give us all wonder drugs now Feb 7, 2006
COST about £30,000 per person per year. BEVACIZUMAB (AVASTIN) for secondary bowel cancer - licensed but waiting Nice approval. ... - ic NorthWales,
Several Additional Angiogenesis Inhibitors are Expected to Reach ... Jan 25, 2006
The breakthrough came in 2004 when the FDA approved Genentechs bevacizumab (Avastin) for colon and rectum cancer and Eyetech Pharmaceuticals pegaptanib (Macugen ... - Genetic Engineering News,
Blockbuster Drugs Generated $166 Billion in Sales in the ... Feb 3, 2006
Among the most important agents fitting this profile are Genentech's Avastin (bevacizumab) for various cancers, Neurochem's Alzhemed/Cerebril for Alzheimer's ... - International News Service,
Addition of Oxaliplatin to FOLFIRI Regimen Increases Survival of ... Jan 30, 2006
Dr. Falcone noted that since the study was initiated in November 2001, doctors have begun using the targeted agent bevacizumab in treatment protocols. ... - DG News
Pro-Pharmaceuticals Receives 'Compassionate Use' IND for Use of ... Feb 2, 2006
The Company has been conducting clinical studies with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (AVASTIN(R ... - International News Service,
Pfizer's Macugen cleared for marketing in EU Feb 3, 2006
Meanwhile, there are a series of other drugs for wet AMD coming through trials, and off-label use of Genentech's cancer drug Avastin (bevacizumab) could also ... - Pharma Times (subscription),
Local cancer centers starts new clinical trial Jan 18, 2006
...patients. Both groups will receive FOLFOX chemotherapy with the Vascular Endothelial Growth Factor inhibitor Bevacizumab (Avastin). ... - Orlando Business Journal,
The prescriptions patients want Jan 7, 2006
Cost - about £30,000 per person per year; Bevacizumab (Avastin) - used as a first-line treatment for secondary bowel cancer. Like ... - ic Wales,
Metronomic chemotherapy plus antiangiogenesis drug has activity in ... Jan 7, 2006
In a pilot study of 55 patients, the combination of low-dose chemotherapy and the anti-VEGF antibody, Bevacizumab ( Avastin ) delayed the breast cancer's ... - Xagena.it,
Combination of Pemetrexed and Oxaliplatin Shows Activity in ... Jan 31, 2006
A phase 2 portion of the study will compare the combination to the modified FOLFOX regimen -- FOLFOX6, with both study arms containing bevacizumab. ... - DG News
Best Oncology Pipeline: Roche Jan 10, 2006
Analysts at Decision Resources (decisionresources.com) say Roche’s Avastin, comprising bevacizumab, will be the primary driver of the market to treat ovarian ... - R&D Directions (subscription),
Record year for Roche's pharma unit Feb 1, 2006
...in sales were the anticancer medicines Herceptin (trastuzumab), which brought in sales of over 2 billion Swiss francs, and Avastin (bevacizumab), which made ... - Pharma Times (subscription),
Genentech Announces Full Year and Fourth Quarter 2005 Results Jan 10, 2006
2004. -- US sales of Avastin(R) (bevacizumab) in 2005 increased 108 percent to $1,132.9 million from $544.6 million in 2004. Fourth ... - MSN Money
Genentech's Shares Fall On Disappointing Avastin Sales Jan 11, 2006
...$544.6 million in 2004. However, the full potential of Avastin (bevacizumab) still has yet to be seen. Genentech has submitted a ... - BioWorld Online (subscription),
Genentech's Q4 profit jumps 64%, but shares slip Jan 11, 2006
And relatively new kid on the block, Avastin (bevacizumab), cleared to treat colon cancer by the US Food and Drug Administration (FDA) in 2004, rocketed 89% to ... - Pharma Times (subscription),
Xanthus: more hurdles to clear for Symadex Jan 17, 2006
Recent entrants such as Genentech/Roche's Avastin (bevacizumab) and ImClone/Bristol-Myers Squibb/Merck KGaA's Erbitux (cetuximab) have also significantly ... - Pharmaceutical Business Review
Genentech Announces Full Year and Fourth Quarter 2005 Results Jan 10, 2006
2004. -- US sales of Avastin® (bevacizumab) in 2005 increased 108 percent to $1,132.9 million from $544.6 million in 2004. Fourth ... - Yahoo! News (press release)
Herceptin plus chemotherapy improves disease-free survival in ... Jan 7, 2006
Jonsson Cancer Center, doctors are testing Herceptin in combination with other targeted therapies such as the angiogenesis inhibitor Avastin ( Bevacizumab ). - Xagena.it,
Streetwise: GM dividend too rich; Genentech worth closer look 15 Jan 2006
Pittsburgh Post Gazette, US sales of Avastin in 2005 increased 108 percent to $1,132.9 million from $544.6 million in 2004. Fourth-quarter Avastin sales ...
UPDATE: Genentech: Avastin Sales Hard To Predict Jan 11, 2006
Business Online, ...officials conceded Wednesday that it will be hard for the company to accurately forecast near-term sales of its popular cancer drug Avastin because doctors ...
Genentech Falls 4% on Avastin Jan 11, 2006
Red Herring, ...profits, but the biotechnology giant’s shares slipped more than four percent Wednesday on lower-than-expected sales of its blockbuster cancer drug Avastin. ...
Genentech's Shares Fall On Disappointing Avastin Sales Jan 11, 2006
BioWorld Online (subscription), Lower-than-expected sales from its flagship cancer drug, Avastin, eclipsed solid fourth-quarter and full-year earnings for Genentech Inc., and caused the ...
Genentech's Avastin Sales Slow For Breast, Lung Cancer Jan 6, 2006
Forbes Research analyst Steven Harr said a recent Morgan Stanley survey of 100 high prescribing oncologists indicated that current use of Avastin for breast and lung ...
Genentech Wants New Avastin Use Dec 19, 2005
TheStreet.com ...commentary - research - Cramer's Take) is seeking regulatory approval to expand the use of its already highly regarded and much-touted cancer drug Avastin. ...
Genentech Seeks Expanded Avastin OK Dec 19, 2005
MSN Money ...(AP) - Genentech Inc. said Monday that it applied to the Food and Drug Administration for a wider approval of its Avastin drug in colon cancer patients. ...
Genentech Submits Supplemental Biologics License Application for ... Dec 19, 2005
Yahoo! News (press release) ...the company has submitted a supplemental Biologics License Application (sBLA) with the US Food and Drug Administration (FDA) for Avastin® (bevacizumab) in ...
Genentech/Roche: expanding Avastin's empire Dec 20, 2005
Pharmaceutical Business Review III clinical performance, Genentech has submitted a supplemental biologics license application for its Roche co-marketed cancer therapy Avastin in relapsed ...
Avastin®/Femara® Combination May Be Promising for Advanced ... Dec 20, 2005
Cancer Consultants (press release), Researchers from the Memorial Sloan-Kettering Cancer Center in New York recently reported that the treatment combination of Avastin (bevacizumab) and Femara ...
Genentech Asks For Expanded Use of Avastin and Pfizer Stocks Jump ... Dec 20, 2005
Financial News USA (press release), USA (OTC: FNWU) Genentech Inc. (NYSE: DNA) has applied for a wider use of its colon cancer drug Avastin. The South San Francisco ...
Genentech asks for expanded use of Avastin Dec 19, 2005
San Francisco Business Times, ...relapsed colon cancer. Right now, Avastin is approved for combination therapy as a first-line treatment in colon cancer. If approved ...
Genentech shares tumble Jan 12, 2006
San Francisco Chronicle, Investors had bid up Genentech's share price by almost 75 percent in 2005, based on growth expectations fueled by the success of its newest cancer drug, Avastin ...
Top Worldwide Jan 10, 2006
Bloomberg The shares fell after sales of the Avastin treatment rose less than analysts expected. ... ``The Avastin number was a little below my number.''. ...
Genentech shares sink more than 4 percent after fourth-quarter ... Jan 11, 2006
Fort Worth Star Telegram, ...recent prosperity largely stems from sales of its flagship product, the non-Hodgkin's lymphoma drug Rituxan, and a relative newcomer called Avastin that has ...
Genentech Says 4th-Qtr Profit Climbs on Cancer Drug Sales Jan 10, 2006
Bloomberg Genentech Inc., the world's second- biggest biotechnology company, said quarterly profit jumped as more doctors prescribed the Avastin and Herceptin cancer ...
Macular degeneration a focus of upcoming symposium in Naples Jan 12, 2006
Naples Daily News (subscription), Eaton still had other treatment options and in August switched her to Avastin, another injectable drug that is similar to Macugen. ...
Genentech Announces Full Year and Fourth Quarter 2005 Results Jan 10, 2006
MSN Money US sales of Avastin(R) (bevacizumab) in 2005 increased 108 percent to $1,132.9 million from $544.6 million in 2004. Fourth quarter ...
(PZ) The Bull Market Report Reviews Genentech's Earnings ... Jan 12, 2006
Houston Chronicle, ...has introduced an element of uncertainty into results, but in our view, the uncertainty is mainly in short-term results -- namely in Avastin sales one quarter ...
Genentech income rises 64% in quarter Jan 11, 2006
San Jose Mercury News, And he added, ``we are very pleased with the successful launch of Avastin and its future potential.'' Avastin is one of Genentech's three main anti-cancer drugs ...
Genentech: An expensive darling Jan 9, 2006
CNN/Money Genentech's three top products are: Herceptin, a breast cancer treatment for patients with a specific gene; Avastin, a treatment for colorectal cancer; and ...
Hopes Were Higher for Genentech Jan 11, 2006
TheStreet.com Merrill Lynch cut the shares to neutral from buy, citing the shortfall in sales of Avastin, the company's latest cancer treatment. ...
PDL Shares Slip on Genentech Results Jan 11, 2006
MSN Money AP) - PDL BioPharma Inc., the biotech firm previously known as Protein Design Labs, saw its shares dip Wednesday after Genentech Inc.'s Avastin cancer drug did ...
Cancer drug sales lift Genentech quarterly profit Jan 10, 2006
Reuters Profile, Research) on Tuesday reported fourth-quarter profit rose 64 percent on surging sales of its cancer medicines, but colon cancer drug Avastin fell short ...
Cancer drug sales lift Genentech quarterly profit Jan 10, 2006
Reuters Profile, Research) on Tuesday reported fourth-quarter profit rose 64 percent on strong sales of its cancer medicines, but colon cancer drug Avastin fell short ...
Genentech's Earnings Skyrocket 64% Jan 11, 2006
Los Angeles Times, ...reported Tuesday that fourth-quarter profit rose 64% on surging sales of its cancer medicines, but colon cancer drug Avastin fell short of lofty Wall Street ...
Investors bail on Genentech after 4th-qtr earnings Jan 11, 2006
MSN Money On Tuesday, after the market closed, it said fourth-quarter profit rose 64 percent. But sales of its colon cancer drug Avastin fell short of expectations. ...
Best Oncology Pipeline: Roche Jan 10, 2006
R&D Directions (subscription), Roche’s oncology business includes five products proven to provide survival benefit in different major tumor indications: Avastin, Herceptin, and Xeloda in ...
Off-label use of cancer drug target of controversy Jan 3, 2006
Shreveport Times, H. James Myrick gets a shot of Avastin in his eye administered by Dr. Charles Lyon at Vitreo-Retinal Associates. (Greg Pearson/The Times). ...
Genentech's Product Mix Could Boost Margins In 2006 Jan 11, 2006
Forbes Genentech reported better-than-expected sales results for Avastin, its colorectal cancer treatment, as well as for Herceptin for breast cancer, and Rituxan for ...
More Upside Expected From Genentech Jan 10, 2006
TheStreet.com 10. In the fourth quarter, Genentech will continue to enjoy easy year-over-year comparisons and outsized gains in its Avastin and Herceptin product lines. ...
Investors bail on Genentech after 4th-qtr earnings Jan 11, 2006
ABC News The company said on Tuesday after the market closed that fourth-quarter profit rose 64 percent, but sales of its colon cancer drug Avastin fell short of ...
Shares fall nearly 4% in pre-open trading Jan 11, 2006
MarketWatch A generally positive earnings report for Genentech Inc, with a 64% hike in earnings, was clouded by concerns that sales of its key Avastin drug were a little ...
New Report Reveals Trends in Cancer Treatment and Emerging ... Jan 11, 2006
PR Newswire (press release), Biologic therapies such as Genentech's Avastin and Herceptin have altered the treatment landscape and other new targeted therapies will no doubt shape clinical ...
Genentech Announces Full Year and Fourth Quarter 2005 Results Jan 10, 2006
Yahoo! News (press release) US sales of Avastin® (bevacizumab) in 2005 increased 108 percent to $1,132.9 million from $544.6 million in 2004. Fourth quarter ...
Genentech up 64% in quarter after good year on many fronts Jan 10, 2006
San Francisco Chronicle, For the full year, Genentech's revenue reached a record $6.6 billion, fed by the sustained growth of its mainstay cancer drugs Rituxan, Herceptin and Avastin. ...
More Big, Boring Growth at Genentech Jan 11, 2006
Motley Fool Likewise, I'm sure there will be some concerns expressed about the slower-than-expected adoption of Avastin in off-label usage. ...
Cancer drug sales lift Genentech quarterly profit Jan 10, 2006
ABC News ...on Tuesday reported fourth-quarter profit rose 64 percent on strong sales of its cancer medicines, but colon cancer drug Avastin fell short of Wall Street ...
Merrill Lynch Cuts Genentech To Neutral From Buy >DNA Jan 11, 2006
New Ratings NEW YORK (Dow Jones)--Merrill Lynch downgraded biotech Genentech (DNA) to neutral from buy, citing Avastin sales that were lower than forecast. ...
US Stock-Index Futures Are Little Changed; Genentech Declines Jan 11, 2006
Bloomberg The world's second-largest biotechnology company said quarterly US sales of Avastin, which is approved to treat colon cancer, climbed 89 percent to $359.1 ...
UPDATE 1-Cancer drug sales lift Genentech quarterly profit Jan 10, 2006
Reuters Fourth-quarter sales of colon cancer drug Avastin, which Genentech eventually expects to be approved to treat several types of cancer, surged 89 percent from a ...
US Stock-Index Futures Pare Gains; DuPont, Genentech Fall Listen Jan 11, 2006
Bloomberg Germany. The company said quarterly US sales of Avastin, which is approved to treat colon cancer, climbed 89 percent to $359.1 million. ...
Genentech scores in 4Q on cancer drug Jan 10, 2006
CNN/Money Biotech firm reports earnings of 34 cents per share helped by Avastin; stock tumbles after hours. NEW YORK (Reuters) - Genentech Inc. ...
New Year's Rally Endures Jan 11, 2006
13WHAM-TV, However, Merrill Lynch downgraded Genentech to neutral from buy after the biotech company reported that sales of Avastin were below estimates. ...
Genentech's Q4 profit jumps 64%, but shares slip Jan 11, 2006
Pharma Times (subscription), And relatively new kid on the block, Avastin (bevacizumab), cleared to treat colon cancer by the US Food and Drug Administration (FDA) in 2004, rocketed 89% to ...
Pro-Pharmaceuticals Announces the Appointment of Anatole Klyosov ... Jan 13, 2006
Genetic Engineering News, ...has been conducting clinical studies with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (AVASTIN(R)). Results ...
Cancer drug sales lift Genentech quarterly profit Jan 10, 2006
Reuters ...(DNA.N: Quote, Profile, Research) on Tuesday reported higher fourth-quarter profit on continued strong sales of its colon cancer drug Avastin and other cancer ...
Cancer drug sales lift Genentech quarterly profit Jan 10, 2006
ABC News ...on Tuesday reported higher fourth-quarter profit on continued strong sales of its colon cancer drug Avastin and other cancer medicines. ...
Swiss shares close markedly higher led by ABB, banks; Roche ... Jan 11, 2006
Forbes Roche underperformed the overall market, down 1 sfr at 193.3 sfr, after slightly disappointing Q4 sales numbers for cancer drug Avastin overnight from Genentech ...
Eye On Stocks For Tuesday, Jan. 10 Jan 9, 2006
Forbes ...today, UBS Investment Research said it expects the company to report another strong quarter tomorrow, driven by positive growth from Avastin, Herceptin and ...
Swiss shares AFX at a glance outlook Jan 10, 2006
Forbes ...higher after losses yesterday, but heavyweight Roche could come under pressure after disappointing fourth quarter sales of cancer drug Avastin at Genentech, in ...
A real surprise Jan 11, 2006
Reuters 16%. Other products experienced faster growth. Sales of cancer treatment Avastin rose 108% to about $1.1 billion. It's possible ...
Eye On Stocks For Wednesday, Jan. 11 Jan 10, 2006
Forbes ...revenue of $1.85 billion. US sales for cancer drug Avastin came in slightly below expectations at $359 million. For fiscal 2006, Genentech ...
Genentech's Profit in Line Jan 10, 2006
TheStreet.com Cramer's Take) fourth-quarter profit was in line with estimates and revenue rose 44% from a year ago as sales of products like Rituxan and Avastin had double ...
Genentech sales and profit soar Jan 10, 2006
San Francisco Business Times, Genentech Inc. reported higher profit in both the fourth quarter and for the full year 2005, driven by strong sales of Avastin, its colon cancer drug. ...
Genentech Endures Drubbing Jan 11, 2006
Smartmoney.com Particularly troubling were sales of Avastin, the company's hot-selling cancer drug, which came in slightly softer than analysts expected. ...
Genentech "neutral," target price raised Jan 11, 2006
New Ratings Genentech has posted higher-than-expected sales of its Herceptin and Rituxan drugs, while Avastin’s sales were short of the consensus, the analysts say. ...
US pre-open: Small rise for stocks Jan 11, 2006
ShareCast, ...operational disruptions. Biotech firm Genentech announced on Tuesday evening that sales of drug Avastin were below estimate. It ...
Roche Up After Genetech 4Q Report Jan 11, 2006
New Ratings Though Genentech's revenue for some treatments - like Rituxan, Avastin and Tarceva - underwhelmed market expecations, says Zuercher Kantonalbank, Roche is ...
Roche Investors Keep Eye On Genentech 4Q Jan 10, 2006
New Ratings ..."The focus of attention will once again be on the extent of off-label use with Avastin in lung cancer and of Herceptin in adjuvant breast cancer," says Lombard ...
US open: Stocks start flat Jan 11, 2006
ShareCast, Biotech firm Genentech saw its shares slide after it announced on Tuesday evening that sales of drug Avastin were below estimate. ...
Stocks Set to Open Up After Recent Gains Jan 11, 2006
Black Enterprise, Frankfurt trade after the biotech overnight reported in-line earnings growth of 64 percent in the fourth quarter, but reported sales of Avastin below consensus ...
Drug companies consider ways to speed up product approvals Jan 14, 2006
San Mateo County Times, These include cancer medicines, such as Novartis AG's Gleevec and Genentech Inc.'s Avastin, designed to turn off molecules that propel tumor growth. ...
Street Chatter: DuPont, Genentech, and SanDisk Jan 11, 2006
Schaeffers Research, The brokerage firm lowered its rating on DNA to "neutral" from "buy," citing Avastin sales that were lower than forecast. "Avastin ...
Genentech seeks sight drug go-ahead Dec 31, 2005
Alameda Times-Star, Lucentis is an antibody fragment similar to the company's cancer drug Avastin, which works by stopping the formation of blood vessels that feedtumors. ...
Cancer drug treats macular degeneration Dec 14, 2005
Savannah Morning News, The 72-year-old widow is among an increasing number of people at risk for central vision loss who are trying Avastin, a cancer drug that inhibits the growth of ...
HSE ‘pressure’ on hospital to withhold cancer drugs Dec 31, 2005
The Sunday Times, Correspondence from last autumn, obtained under the Freedom of Information Act, reveals that the hospital wants more money for Herceptin and Avastin, top-end ...
Biotechs Start 2006 With Big Gains Jan 7, 2006
Forbes The decline may have been sparked by a Morgan Stanley research report published Friday that said growth remains sluggish for Avastin in the treatment of breast ...
Earnings Outlook Genentech earnings to roll next week Jan 6, 2006
MarketWatch Piper Jaffray expects the focus of the earnings release and the subsequent conference call to be on the company's 2006 outlook, along with Herceptin and Avastin ...
What, Us Worry? Jan 13, 2006
Forbes If you want to benefit of Genentech's (nyse: DNA - news - people ) Avastin for colon cancer, you need to accept that there is a risk of bleeding that comes ...
US Stock-Index Futures Advance; Apple, Broadcom Shares Rise Jan 11, 2006
Bloomberg ...$88.95. The company said fourth- quarter US sales of Avastin, which treats colon cancer, climbed 89 percent to $359.1 million. That ...
Drugs in '05: Much Promise, Little Payoff Jan 10, 2006
New York Times, In 2004, important cancer treatments including Avastin, by Genentech, and Tarceva, through a partnership of Genentech and OSI Pharmaceuticals, were among the ...
Genentech "outperform," estimates reduced Jan 12, 2006
New Ratings Genentech posted robust revenues from its Herceptin and Rituxan drugs and lower-than-consensus US Avastin revenues, the analyst says. ...
US close: Dow still above 11,000 Jan 11, 2006
ShareCast, ...operational disruptions. Genentech suffered after it announced on Tuesday evening that sales of drug Avastin were below estimate. It ...
Genentech "overweight," target price reduced Jan 12, 2006
New Ratings ...healthy fundamentals. Genentech has posted its quarterly sales for Avastin and Rituxan ahead of the estimates and the consensus. The ...
Genentech, Biogen Idec sued over Rituxan marketing Jan 12, 2006
North County Times, Idec had built in Oceanside. Genentech is now preparing the plant to make another cancer drug, Avastin. Genentech was served with ...
Cancer drug finds new life in China Dec 22, 2005
Pittsburgh Post Gazette, He was largely vindicated in February 2004 when the US Food and Drug Administration approved Avastin, a cancer drug based on this principle. ...
Genaera Shares Drop on Competition Worries Jan 4, 2006
MSN Money ...the therapy to prove effective in these studies, but said the market is already shrinking because of off-label use of Genentech Inc.'s Avastin cancer drug and ...
PDL Grants Patent Licenses to Merck for Humanized Antibodies ... Jan 3, 2006
PR Newswire (press release), Companies currently holding patent licenses for marketed products are Genentech, Inc. (Herceptin(R), Xolair(R), Raptiva(R) and Avastin(TM)); MedImmune, Inc. ...
Metronomic chemotherapy plus antiangiogenesis drug has activity in ... Jan 7, 2006
Xagena.it, In a pilot study of 55 patients, the combination of low-dose chemotherapy and the anti-VEGF antibody, Bevacizumab ( Avastin ) delayed the breast cancer's ...
US Stocks Resume Rally as Apple, Technology Shares Gain Listen Jan 11, 2006
Bloomberg ...$89.22. The company said fourth-quarter US sales of Avastin, which treats colon cancer, climbed 89 percent to $359.1 million. That ...
Cancer mum's tumour shrinks by 40% after a SINGLE dose Dec 18, 2005
Mirror.co.uk, ...for. The 26-year-old, who has colon and liver cancer, was initially denied the "smart pill" Avastin because it cost too much. But ...
Genentech Submits Lucentis BLA For Age-Related AMD Dec 30, 2005
BioWorld Online (subscription), The lowered estimate came as a result of more retinal specialists trying Genentech's VEGF inhibitor for colorectal cancer Avastin (bevacizumab) for wet AMD. ...
Genentech Asks OK for Eye Drug Dec 30, 2005
Red Herring, Like the company’s top-performing cancer drug, Avastin, it is based on human antibody technology and is designed to block new blood vessel growth, a process ...
Targeted cancer therapies: Another step forward Dec 22, 2005
News-Medical.net, ...therapies market will be driven mainly by five key products: Genentech/Roches Rituxan (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab), Tarceva ...
Regeneron shares rise on analyst upgrade Dec 27, 2005
BusinessWeek ...from an analyst optimistic about the company's experimental drug, VEGF Trap, which could prove to be a competitor for Genentech Inc.'s cancer drug Avastin. ...
Genentech heads toward completion of Oceanside plant Dec 14, 2005
North County Times, That broth contains one of the biggest-selling drugs for biotech giant Genentech Inc.: a compound called Avastin that treats metastatic cancer of the colon or ...
Targeted cancer therapies: another step forward Dec 23, 2005
Pharmaceutical Business Review ...market is expected to be driven mainly by five key products: Genentech/Roche’s Rituxan (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab), Tarceva ...
Euroshares outlook - higher after Wall Street gains, BP in focus Jan 10, 2006
Forbes Roche is likely to be pressured after disappointing Avastin sales weighed on Genentech -- in which the Swiss group has a 51 pct stake -- in afer-hours trade. ...
Investors wary after run Jan 11, 2006
CNN International The drugmaker said sales of its colon cancer treatment Avastin were short of estimates, which overshadowed its higher quarterly earnings that were in line with ...
Swiss shares continue higher on rebound, Baloise, ABB, banks ... Jan 11, 2006
Forbes ...top loser, underperforming the overall market, down 3.8 sfr at 190.7 sfr, after slightly disappointing Q4 sales numbers for cancer drug Avastin overnight from ...
Swiss shares close markedly higher led by ABB, banks;Roche ... Jan 11, 2006
Forbes ...the overall market, but closed off earlier lows, down 1 sfr at 193.3 sfr, after slightly disappointing Q4 sales numbers for cancer drug Avastin overnight from ...
US stocks end higher; Nasdaq up seven in a row Jan 11, 2006
MarketWatch ...dropped Wednesday after the biotechnology giant's fourth-quarter earnings report raised concerns on Wall Street over sales of its key Avastin drug. ...
Roche bucks softer sector ahead of Genentech Q4 Jan 10, 2006
Reuters ..."The focus of attention will once again be on the extent of off-label use with Avastin in lung cancer and of Herceptin in (HER2+) adjuvant breast cancer," LODH ...
Quiet open for Wall Street Jan 11, 2006
Boston Herald, Genentech shares edged lower in after-hours trading, amid concern about sales of Avastin, used to treat patients with colon cancer. ...
Health Stocks in Motion Jan 11, 2006
TheStreet.com Following the earnings report, Merrill Lynch downgraded Genentech to neutral from buy, citing lower-than-expected sales of the cancer drug Avastin. ...
